Skip to main content

Table 1 Baseline Demographics by Use of Any Substance (yes vs. no) primary analysis set

From: Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study

  

Any Substance Use

 

Parameter

 

Yes (n = 116)

No (n = 53)

Overall (n = 169)

Age at Consent (years) a

Valid n

116

53

169

Mean [SD (95% CI)]

31.4 [11.47 (29.4, 33.6)]

35.9[13.20 (32.3, 39.6)

32.9[12.18 (31.0, 34.7)

Min, max

18, 67

18, 69

18, 69

Gender, n (%)

Male

90 (77.6)

24 (45.3)

114 (67.5)

Female

26 (22.4)

29 (54.7)

55 (32.5)

Race, n (%)

Caucasian

98 (84.5)

31 (58.5)

129 (76.3)

Black

9 (7.8)

13 (24.5)

22 (13.0)

Asian

3 (2.6)

5 (9.4)

8 (4.7)

Other

6 (5.2)

4 (7.5)

10 (5.9)

Region, n (%)

British Columbia

10 (8.6)

1 (1.9)

11 (6.5)

Prairies1

19 (16.4)

11 (20.8)

30 (17.8)

Ontario

31 (26.7

17 (32.1)

48 (28.4)

Quebec

51 (44.0)

24 (45.3)

75 (44.4)

Eastern2

5 (4.3)

 

5 (3.0)

  1. 1Prairies = Alberta, Saskatchewan, and Manitoba
  2. 2Eastern = New Brunswick, Newfoundland, Nova Scotia and Prince Edward Island
  3. aAge at consent (years) = int[(ICF signed date)-Date of Birth + 1)/365.25]
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us